Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
AD

ADRXStockADARx Pharmaceuticals, Inc.

Healthcare

$14.00 last close 2026-11-16
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ADRX's does — no target price to set, unlike a price alert.

Stable Ratio screen, 0 of 4 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine · assessed 2026-09-23
0 of 4 pass our own screen — 3 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

ADARx Pharmaceuticals, Inc. (ADRX) is currently considered not halal (non-compliant), per our in-house ratio engine (last assessed 2026-09-23). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

436 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$34.25
+144.6% · 4 analysts
Institutional own.
82.9%
of shares
$34.25
Price target (+144.6%) · 4 analysts
82.9%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap stored with these figures ($1.6B); this record does not say which day it was fetched, so no estimate for today is made from it.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.41% 30.00% Pass(29.6pp buffer)
Interest-bearing investments 57.25% 30.00% Fail(27.2pp over)
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.70% 33.00% Pass(32.3pp buffer)
Interest-bearing investments 96.98% 33.00% Fail(64.0pp over)
Non-liquid assets 3.02% at least 20.00% Fail(17.0pp below the floor)
MSCI Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.70% 33.33% Pass(32.6pp buffer)
Cash + interest-bearing securities 96.98% 33.33% Fail(63.7pp over)
Accounts receivable 96.98% 33.33% Fail(63.7pp over)
FTSE Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 96.98% 33.33% Fail(63.6pp over)
Accounts receivable 96.98% 50.00% Fail(47.0pp over)

ℹ️ Dow Jones Islamic Market, MSCI M-Series, S&P Shariah divide by a trailing-average market cap (24- or 36-month) rather than today's. That price history is not collected for non-US listings, so these are reported as unverified — it reflects a missing input on our side, not anything about the company.

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)debt ratio 29.6pts
Usmani (% of total assets)debt ratio 32.3pts
MSCI Islamic Index (% of total assets)debt ratio 32.6pts
Usmani (% of total assets)investments ratio 64.0pts
MSCI Islamic Index (% of total assets)cash and interest ratio 63.7pts
MSCI Islamic Index (% of total assets)receivables ratio 63.7pts

The numbers the ratios are built from

Read from ADRX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $901.0M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, ShortTermInvestments
Total assetsBalance sheet total $929.1M 2026-09-30 Assets
Market capDenominator for AAOIFI $1.6B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market not measured — —
Non-permissible revenueInterest and excluded income not measured — —

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Screened 2026-11-16.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$929.1M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$901.0M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, ShortTermInvestments · balance sheet as of 2026-09-30
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Market cap$1.6B
    Market-data quote at screen time, 2026-11-16 · not a filing figure, so no link

What changed, and when

Verdict history for ADRX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for ADRX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 4 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (0.4% against a 30% line) would only fail if the market cap fell by 99%, to $21.5M.

AAOIFI's investments ratio is $901.0M cash and interest-bearing investments over a market cap of $1.6B, 57.2% against a 30% line.

It would pass if the market cap rose above $3.0B (+91%), about $27.01 a share against $14.15 implied by the screen's own figures.

AAOIFI would then be unverified, and the majority verdict would move from Not compliant to no verdict (0 of 3 decided standards passing).

At the screen's market cap, it would take $428.9M less cash and interest-bearing investments to clear the line.

AAOIFI would then be unverified, and the majority verdict would move from Not compliant to no verdict (0 of 3 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding ADRX
InvestorFirmPositionWeightAs of
Israel Englander Millennium Management $9M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $7M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

20.6418.7916.9315.0813.232026-09-252026-10-212026-11-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
10.74
S2
12.22
S1
13.21
PIVOT
14.69
R1
15.68
R2
17.16
R3
18.15

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
9.50 – 17.08
±28.48% from 13.29, made 2026-11-06 · resolves 2026-11-13
STRONG SELL
from 13 indicators
74.1% of our last 15548 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.3% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
14 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 7 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)36.10NEUTRAL
Stochastic %K (14)24.00NEUTRAL
CCI (20)-72.85NEUTRAL
Williams %R (14)-76.00NEUTRAL
MACD (12,26,9)-0.12SELL
ROC (10)-11.17SELL
Momentum (10)-1.76SELL
EMA (10)14.50SELL
SMA (10)14.13SELL
EMA (20)15.46SELL
SMA (20)15.80SELL
EMA (30)16.34SELL
SMA (30)16.46SELL
EMA (50)17.05SELL

About ADARx Pharmaceuticals, Inc.

Healthcare · Biotechnology

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

adarx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

Still fetching the market-structure read — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.